Vertex Pharmaceuticals Incorporated Website

Vertex Pharmaceuticals Incorporated

NasdaqGS-VRTX

Basic

  • Market Cap

    $126.12B

  • EV

    $112.29B

  • Shares Out

    258.05M

  • Revenue

    $10.19B

  • Employees

    5,400

Margins

  • Gross

    55.35%

  • EBITDA

    45%

  • Operating

    43.2%

  • Pre-Tax

    46.81%

  • Net

    39.46%

  • FCF

    36.5%

Returns (5Yr Avg)

  • ROA

    22.42%

  • ROTA

    31.63%

  • ROE

    30.53%

  • ROCE

    30.16%

  • ROIC

    70.54%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $473.09

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $10.17B

  • Net Debt

    -$13.83B

  • Debt/Equity

    0.04

  • EBIT/Interest

    102.08

Growth (CAGR)

  • Rev 3Yr

    16.66%

  • Rev 5Yr

    25.55%

  • Rev 10Yr

    26.1%

  • Dil EPS 3Yr

    13.67%

  • Dil EPS 5Yr

    13.18%

  • Dil EPS 10Yr

    25.3%

  • Rev Fwd 2Yr

    8.77%

  • EBITDA Fwd 2Yr

    12.19%

  • EPS Fwd 2Yr

    9.24%

  • EPS LT Growth Est

    30.17%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Operating Revenues

4,160.7

6,202.8

7,573.4

8,930.7

9,869.2

10,185

Other Revenues, Total

2.1

2.9

1

Total Revenues

4,162.8

6,205.7

7,574.4

8,930.7

9,869.2

10,185

Total Revenues % Chg.

36.6%

49.1%

22.1%

17.9%

10.5%

10.6%

Cost of Goods Sold, Total

2,302.3

2,381.2

2,842

3,607.6

4,425.1

4,547.3

Gross Profit

1,860.5

3,824.5

4,732.4

5,323.1

5,444.1

5,637.7

Selling General & Admin Expenses, Total

658.5

770.5

840.1

944.7

1,136.6

1,238.2

Other Operating Expenses, Total

658.5

770.5

840.1

944.7

1,136.6

1,238.2

Operating Income

1,202

3,054

3,892.3

4,378.4

4,307.5

4,399.5

Interest Expense, Total

-58.5

-58.2

-61.5

-54.8

-44.1

-43.1

Interest And Investment Income

63.7

22.2

4.9

144.6

614.7

673.3

Net Interest Expenses

5.2

-36

-56.6

89.8

570.6

630.2

Currency Exchange Gains (Loss)

-5.2

-16.1

-13.9

-15.1

-24.6

-30.6

Other Non Operating Income (Expenses)

-0.2

0.8

1.7

-0.6

9.3

-8.1

EBT, Excl. Unusual Items

1,201.8

3,002.7

3,823.5

4,452.5

4,862.8

4,991

Restructuring Charges

Gain (Loss) On Sale Of Investments

197.6

311.9

17.1

-149.1

-7.5

-16.6

Gain (Loss) On Sale Of Assets

Asset Writedown

-13

In Process R&D Expenses

-184.6

-1,113.3

-115.5

-527.1

-256.8

Other Unusual Items

-4.5

-13.1

3.1

57.5

51.6

49.8

EBT, Incl. Unusual Items

1,394.9

3,116.9

2,730.4

4,232.4

4,379.8

4,767.4

Income Tax Expense

218.1

405.2

388.3

910.4

760.2

748

Earnings From Continuing Operations

1,176.8

2,711.7

2,342.1

3,322

3,619.6

4,019.4

Earnings Of Discontinued Operations

Minority Interest

Net Income

1,176.8

2,711.7

2,342.1

3,322

3,619.6

4,019.4

Preferred Dividend and Other Adjustments

Net Income to Common Incl Extra Items

1,176.8

2,711.7

2,342.1

3,322

3,619.6

4,019.4

Net Income to Common Excl. Extra Items

1,176.8

2,711.7

2,342.1

3,322

3,619.6

4,019.4

Total Shares Outstanding

259

259.9

254.5

257

257.7

258.3

Weighted Avg. Shares Outstanding

256.7

259.8

257.7

256.1

257.7

257.9

Weighted Avg. Shares Outstanding Dil

260.7

263.4

259.9

259.1

260.5

260.7

EPS

4.6

10.4

9.1

13

14

15.6

EPS Diluted

4.5

10.3

9

12.8

13.9

15.4

EBITDA

1,308.9

3,163.5

4,017.9

4,526.7

4,477

4,583.7

Effective Tax Rate

15.6%

13%

14.2%

21.5%

17.4%

15.7%